Compare Newmont Corporation (NEM) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Newmont Corporation vs Tempus AI — how do they compare? Newmont Corporation trades at $117.94 (market cap $119.64B), while Tempus AI trades at $70.19 (market cap $12.77B). The key difference: Newmont Corporation is far larger — about 9.4× Tempus AI's market cap, and Newmont Corporation pays a 0.92% dividend while Tempus AI pays none. Which is the better fit depends on your goals — on Pluang, investors hold Newmont Corporation for 58 Days and Tempus AI for 22 Days on average.
| NEM | TEM | |
|---|---|---|
Market Cap | $119.64B | $12.77B |
Volume | 4,343,460 | 8,980,490 |
Sector | Basic Materials | Broad Market / Factor |
52-Week High | $135.14 | $99.28 |
52-Week Low | $78.63 | $41.55 |
Typical Hold Time | 58 Days | 22 Days |
Enterprise Value | $116.23B | $13.40B |
Dividend Yield | 0.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Newmont (NEM) trades at $113.54, down 2.45% on the day, amid a bearish technical signal but strong fundamental performance. The company reported record free cash flow of $5.3 billion in H1 2026 and has beaten earnings estimates for three consecutive quarters. Revenue grew to $22.67 billion in 2025 with a net income margin of 33.36%, while analyst consensus remains strongly bullish with a $136.83 price target.
The stock presents a compelling value opportunity with a P/E of 14.32 and robust profitability, though near-term technical weakness and gold price volatility pose risks. Upside potential is supported by operational improvements and shareholder returns, but investors must weigh macroeconomic factors affecting the gold sector.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite negative profitability. Recent FDA clearance for its ECG-MR AI product and 13 abstracts accepted for ESMO Congress 2026 highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist. The stock shows strong analyst support with a $72.60 consensus target and 64% buy ratings.
Outlook remains cautiously optimistic driven by AI healthcare adoption and data licensing growth, but high valuation multiples and sustained losses pose risks. Investor sentiment is positive amid recent insider selling and institutional interest, yet profitability challenges and competitive pressures require monitoring for long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
